<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00915187</url>
  </required_header>
  <id_info>
    <org_study_id>NX09-4</org_study_id>
    <nct_id>NCT00915187</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity Study of Intramuscular CCS/C-adjuvanted Influenza Vaccine in Elderly</brief_title>
  <official_title>A Phase II Safety and Immunogenicity Study of Intramuscular CCS/C-adjuvanted Influenza Vaccine in Elderly, a Double-blind Randomized, Controlled Single Center Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NasVax Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NasVax Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To examine the safety and immunogenicity of two formulation of liposomal adjuvant / delivery
      system (VaxiSomeTM=CCS-Cholesterol [CCS/C]), combined with commercial influenza vaccine in an
      elderly healthy population when given once intramuscularly (IM).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity will be evaluated according to the CHMP criteria for evaluation of flu vaccines, i.e., Seroprotection, Geometric Mean Ratios, and Seroconversion rate</measure>
    <time_frame>Day 28 following vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity will be evaluated according to the CHMP criteria for evaluation of flu vaccines, i.e., Seroprotection, Geometric Mean Ratios, and Seroconversion rate</measure>
    <time_frame>Day 90 following vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CCS/C (Adjuvant Formulation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CCS/C</intervention_name>
    <description>Adjuvant to influenza vaccine</description>
    <arm_group_label>CCS/C (Adjuvant Formulation)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza Vaccine</intervention_name>
    <description>Influenza vaccine</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  65 years of age or older, mentally competent, willing and able to give written
             informed consent prior to study entry, male or female;

          -  able to comply with all the study requirements;

          -  in stable good health as determined by medical history; physical examination; clinical
             judgment of the investigator.

          -  Have adequate renal function (renal clearance of at &gt; 30ml/min)

          -  Have normal liver function (hepatic transaminases [ALT and AST] &lt; 43 U/L)

          -  Have hemoglobin &gt; 11.5 g/L

        Exclusion Criteria:

          -  Any serious chronic or acute disease (in the judgment of the investigator) including
             but not limited to: cancer, except for localized skin cancer;

          -  Advanced congestive heart failure; Acute exacerbation of Chronic obstructive pulmonary
             disease (COPD); Autoimmune disease, Acute or progressive hepatic disease; Acute or
             progressive renal disease with a renal clearance of at &lt; 30ml/min ; Severe
             neurological or psychiatric disorder; History of Guillain Barr√© syndrome; Severe
             asthma.

          -  Clinically significant symptoms of neurological disease; untreated hypertension;
             increased liver enzymes.

          -  History of any anaphylactic reaction and/or serious allergic reaction following a
             vaccination
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoseph Caraco, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Pharmacology Unit, Division of Medicine, Hadassah University Hospital Jerusalem, Israel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Pharmacology Unit, Division of Medicine, Hadassah University Hospital</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2009</study_first_submitted>
  <study_first_submitted_qc>June 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2009</study_first_posted>
  <last_update_submitted>October 18, 2011</last_update_submitted>
  <last_update_submitted_qc>October 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccination, influenza prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

